Low dose of MRM-3379 + Middle Dose of MRM-3379 + High dose of MRM-3379 + Placebo + Low dose of MRM-3379 Open-Label

Phase 2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Fragile X Syndrome

Conditions

Fragile X Syndrome

Trial Timeline

Nov 22, 2025 → Oct 1, 2027

NCT ID

NCT07209462

About Low dose of MRM-3379 + Middle Dose of MRM-3379 + High dose of MRM-3379 + Placebo + Low dose of MRM-3379 Open-Label

Low dose of MRM-3379 + Middle Dose of MRM-3379 + High dose of MRM-3379 + Placebo + Low dose of MRM-3379 Open-Label is a phase 2 stage product being developed by Mirum Pharmaceuticals for Fragile X Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07209462. Target conditions include Fragile X Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07209462	Phase 2	Recruiting	Nov 22, 2025	Oct 1, 2027	Fragile X Syndrome

Competing Products

14 competing products in Fragile X Syndrome

See all competitors

Product	Company	Stage	Hype Score
CTH120	Connecta Therapeutics	Phase 1	19
AFQ056	Novartis	Phase 1	29
AFQ056	Novartis	Phase 2/3	30
AFQ056 + Placebo	Novartis	Phase 2	35
AFQ056 + Placebo	Novartis	Phase 2	35
AFQ056	Novartis	Phase 2	27
AFQ056 + Placebo	Novartis	Phase 2	35
AF056 + Placebo	Novartis	Phase 2	35
Placebo + RO4917523 + RO4917523	Roche	Phase 2	35
Placebo (for RO4917523 ascending doses) + Placebo (for RO4917523 fixed dose) + RO4917523 + RO4917523	Roche	Phase 2	35
Placebo + RO4917523 0.5 mg + RO4917523 1.5 mg	Roche	Phase 2	35
CBD Oral Solution + Placebo	Jazz Pharmaceuticals	Phase 2	39
CBD Oral Solution (eCBD system Target) + Placebo	Jazz Pharmaceuticals	Phase 2	39
NNZ-2566 + Placebo	Neuren Pharmaceuticals	Phase 2	29